格列本脲联合医学营养支持对妊娠期糖尿病患者血糖控制和妊娠结局的影响  

Effect of Glibenclamide Combined with Medical Nutrition Support on Blood Glucose Control and Pregnancy Outcome in Patients with Gestational Diabetes

作　　者：郅红 ZHI Hong(Department of Pregnancy Health,Xintai Maternal and Child Health and Family Planning Service Center,Tai'an 271200,China)

机构地区：[1]新泰市妇幼保健计划生育服务中心孕期保健科,山东泰安271200

出　　处：《反射疗法与康复医学》2024年第17期108-111,共4页Reflexology And Rehabilitation Medicine

摘　　要：目的观察妊娠期糖尿病患者联合应用格列本脲、医学营养支持治疗的临床效果。方法选取2022年1月—2023年1月我院收治的80例妊娠期糖尿病患者为研究对象,按随机数字表法将其分为对照组和观察组,各40例。入院后均进行常规基础治疗,在此基础上对照组配合医学营养支持治疗,观察组配合医学营养支持治疗同时加用格列本脲。比较两组的血糖控制优良率、孕期体质量、血糖水平、胰岛素水平、妊娠结局、新生儿结局。结果观察组患者血糖控制优良率为92.50%,高于对照组的72.50%,差异有统计学意义(P<0.05)。治疗前,两组患者孕期体质指数(BMI)、空腹血糖(FPG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)水平比较,组间差异无统计学意义(P>0.05);治疗后,观察组患者孕期BMI(26.03±1.52)kg/m^(2)、FPG(6.23±0.99)mmol/L、FINS(11.01±1.62)mU/L、HbA1c(6.16±0.71)%均低于对照组的(28.61±1.73)kg/m^(2)、(7.74±0.91)mmol/L、(13.76±1.58)mU/L、(7.08±0.75)%,组间差异有统计学意义(P<0.05)。观察组患者早产率22.50%、剖宫率32.50%、羊水异常率12.50%、胎膜早破发生率17.50%、产后出血发生率22.50%、产褥感染发生率15.00%均低于对照组的45.00%、55.00%、32.50%、37.50%、50.00%、37.50%,组间差异有统计学意义(P<0.05)。观察组胎儿宫内窘迫发生率10.00%、新生儿窒息发生率2.50%、新生儿低血糖发生率7.50%、新生儿感染发生率5.00%、新生儿高胆红素血症发生率2.50%均低于对照组的32.50%、20.00%、30.00%、25.00%、22.50%,组间差异有统计学意义(P<0.05)。结论妊娠期糖尿病患者在医学营养支持治疗基础上加用格列本脲,能够显著提高血糖控制效果,改善孕期体质量,降低空腹胰岛素水平,优化妊娠结局,提升人口出生质量。Objective To observe and explore the clinical effect of glibenclamide combined with medical nutrition support in patients with gestational diabetes,and the influence of blood glucose control and pregnancy outcome.Methods A total of 80 patients with gestational diabetes received by our hospital from January 2022 to January 2023 were selected as research objects,and they were divided into a control group and an observation group using a random number table method,with 40 cases in each group.After admission,all patients received routine basic treatment.On this basis,the control group was treated with medical nutritional support,while the observation group was treated with medical nutritional support and added with glibenclamide.Compare the excellent blood glucose control rates,gestational body mass,blood glucose levels,insulin levels,pregnancy outcomes,and neonatal outcomes between two groups.Results The excellent rate of blood glucose control in the observation group was 92.50%,which was higher than 72.50%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no difference in Body Mass Index(BMI),Fasting Plasma Glucose(FPG),Fasting Insulin(FINS),and Hemoglobin A1c(HbA1c)between the two groups of patients(P>0.05);after treatment,the observation group had lower pregnancy BMI(26.03±1.52)kg/m^(2),FPG(6.23±0.99)mmol/L,FINS(11.01±1.62)mU/L,and HbA1c(6.16±0.71)%compared to the control group(28.61±1.73)kg/m^(2),(7.74±0.91)mmol/L,(13.76±1.58)mU/L,and(7.08±0.75)%,and the differences were statistically significant(P<0.05).The observation group had a premature birth rate of 22.50%,a cesarean section rate of 32.50%,an abnormal amniotic fluid rate of 12.50%,an incidence of premature rupture of membranes of 17.50%,an incidence of postpartum hemorrhage of 22.50%,and an incidence of postpartum infection of 15.00%,all were lower than the control group's 45.00%,55.00%,32.50%,37.50%,50.00%,and 37.50%,and the differences were statistically significant(P<0.05).The incidence of fe

关 键 词：妊娠期糖尿病 格列本脲 医学营养支持 血糖控制 妊娠结局 新生儿结局 

分 类 号：R714[医药卫生—妇产科学]